PTAB Says Sandoz Rehashed Arguments In Rituxan IP Challenge
Law360 (April 5, 2018, 6:32 PM EDT) — The Patent Trial and Appeal Board rejected challenges from Sandoz Inc. to a patent covering Genentech Inc.’s biologic Rituxan after finding they were too similar to ones brought by another biosimilar maker, but agreed to institute review in Pfizer Inc.’s challenge of …